Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Efficacy Standards For 55 Diseases In 5 Years: FDA, Critical Path And CDISC’s Ambitious Plan

Executive Summary

Building on the Alzheimer’s disease Therapeutic Area Standard, the groups hope to create measurement standards for clinical trials in a variety of therapeutic areas, but funding remains an acute challenge. In order to succeed, each project needs to be faster and cheaper than the Alzheimer’s effort.

You may also be interested in...



FDA Therapeutic Area Standards Would Have To Clear Industry Testing

Validation rules for standardized clinical trial data terminology could allow sponsors to check their data in the same way FDA does.

FDA Clinical Data Standards-Setting Likely To Run Longer Than Five Years

Agency’s goal of setting standards for clinical data in 57 therapeutic areas in five years looks unlikely to be met, according to the timelines given by members of the Coalition For Accelerating Standards and Therapies.

FDA Data-Standards Landslide: CDISC’s Model Wins Docket Comment Contest

Overwhelming number of stakeholders urge FDA to choose the Clinical Data Interchange Standards Consortium’s Operational Data Model instead of the competing Health Level 7 standard for clinical data submissions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS054045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel